PE20050488A1 - Formas de administracion masticables, no comprimidas, dosificadas individualmente - Google Patents

Formas de administracion masticables, no comprimidas, dosificadas individualmente

Info

Publication number
PE20050488A1
PE20050488A1 PE2004001080A PE2004001080A PE20050488A1 PE 20050488 A1 PE20050488 A1 PE 20050488A1 PE 2004001080 A PE2004001080 A PE 2004001080A PE 2004001080 A PE2004001080 A PE 2004001080A PE 20050488 A1 PE20050488 A1 PE 20050488A1
Authority
PE
Peru
Prior art keywords
water
chewable
administration
individually dosed
weight
Prior art date
Application number
PE2004001080A
Other languages
English (en)
Inventor
Gonzalez Nuria Garcia
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Coll Pere Guiro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of PE20050488A1 publication Critical patent/PE20050488A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UNA COMPOSICION COMPRENDIDA POR: A) UNA SUSTANCIA FARMACEUTICA DISUELTA EN UN B) MATERIAL MATRIZ QUE COMPRENDE UNA MEZCLA DE: 1) 0,2% EN PESO DE GELATINA, 2) UN AGENTE ESTABILIZADOR, 3) UN ALCOHOL SOLUBLE EN AGUA, Y 4) AGUA. DICHO ESTABILIZADOR SE CARACTERIZA POR SER ESTER DE GLICERINA, PRODUCTO ORIGINADO POR ALCOHOLISIS/ESTERIFICACION DE DICHO ESTER CON POLIETILENGLICOLES Y TENER UN PUNTO DE FUSION ENTRE 42°C A 63°C. EL AGUA NO EXCEDE AL 46% EN PESO DEL TOTAL DE LA COMPOSICION LA CUAL SE PRESENTA COMO GEL MASTICABLE NO COMPRIMIDO ENVASADO EN BLISTER O CAVIDADES
PE2004001080A 2003-11-10 2004-11-05 Formas de administracion masticables, no comprimidas, dosificadas individualmente PE20050488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
PE20050488A1 true PE20050488A1 (es) 2005-08-24

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001080A PE20050488A1 (es) 2003-11-10 2004-11-05 Formas de administracion masticables, no comprimidas, dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (es)
EP (1) EP1682097B1 (es)
JP (1) JP4879021B2 (es)
KR (1) KR20060116821A (es)
CN (1) CN1878542A (es)
AR (1) AR048050A1 (es)
AT (1) ATE492270T1 (es)
AU (1) AU2004290517B2 (es)
BR (1) BRPI0416215A (es)
CA (1) CA2548615A1 (es)
CO (1) CO5690531A2 (es)
DE (1) DE602004030706D1 (es)
EC (1) ECSP066553A (es)
ES (2) ES2235626B1 (es)
IL (1) IL175285A (es)
MY (1) MY143793A (es)
NO (1) NO20062723L (es)
NZ (1) NZ546375A (es)
PE (1) PE20050488A1 (es)
RU (1) RU2369379C2 (es)
TW (1) TW200526266A (es)
UA (1) UA90253C2 (es)
UY (1) UY28586A1 (es)
WO (2) WO2005048975A1 (es)
ZA (1) ZA200602416B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EP2170282A4 (en) * 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
EA023758B1 (ru) 2009-06-25 2016-07-29 Алкобра Лтд. Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add)
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114667146A (zh) 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
PE20231815A1 (es) 2021-02-09 2023-11-16 Xenon Pharmaceuticals Inc Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
JP4879021B2 (ja) 2012-02-15
ECSP066553A (es) 2006-12-20
KR20060116821A (ko) 2006-11-15
WO2005048974A3 (en) 2006-02-23
JP2007510690A (ja) 2007-04-26
ES2358332T3 (es) 2011-05-09
ES2235626B1 (es) 2006-11-01
AU2004290517A1 (en) 2005-06-02
CN1878542A (zh) 2006-12-13
ZA200602416B (en) 2009-06-24
CO5690531A2 (es) 2006-10-31
NO20062723L (no) 2006-06-12
CA2548615A1 (en) 2005-06-02
ATE492270T1 (de) 2011-01-15
MY143793A (en) 2011-07-15
AR048050A1 (es) 2006-03-29
RU2369379C2 (ru) 2009-10-10
AU2004290517B2 (en) 2010-05-27
EP1682097A2 (en) 2006-07-26
IL175285A (en) 2011-04-28
TW200526266A (en) 2005-08-16
US20070134318A1 (en) 2007-06-14
BRPI0416215A (pt) 2006-12-26
NZ546375A (en) 2009-11-27
RU2006120087A (ru) 2007-12-27
DE602004030706D1 (de) 2011-02-03
UY28586A1 (es) 2005-05-31
WO2005048975A1 (en) 2005-06-02
UA90253C2 (ru) 2010-04-26
IL175285A0 (en) 2006-09-05
ES2235626A1 (es) 2005-07-01
EP1682097B1 (en) 2010-12-22
WO2005048974A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
CO5690531A2 (es) Formas de administracion masticables, no comprimidas dosificadas individualmente
AR048250A1 (es) Productos de pelicula que tienen propiedades de disgregacion controlada
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
ES2095043T3 (es) Composicion para preparados orales.
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
ES2002302A6 (es) Una capsula de gelatina dura que contiene una composicion masticable
MX171463B (es) Sistema de dosificacion de liberacion sostenida y procedimiento para su preparacion
CO5680461A2 (es) Productos farmaceuticos que comprenden bisfosfonatos
AR002266A1 (es) Composicion farmaceutica de gelatina blanda o forma de dosis que la incluye
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
NO20010264L (no) Bionedbrytbare preparater for kontrollert frigivelse av innkapslede stoffer
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
PE20100123A1 (es) Una formulacion solida de dosificacion farmaceutica
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
JP2017533914A (ja) 胃内滞留性ゲル製剤
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
NO20030897L (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
PE20050464A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed